The Seattle Mariners have been given a 57.9 percent chance to make the playoffs in 2025, according to the latest projections from the PECOTA model (Baseball Prospectus). One year after going 85-77 ...

But there’s a major catch: he wants the app to operate under 50 percent U.S. ownership. Apparently reacting to Trump’s promises, TikTok issued a statement saying, “In agreement with our ...

CBS-owned Paramount+ is offering a 50 percent discount on its annual plans in Canada. The deal is part of a limited-time promotion. Until February 1st, 2024, users can subscribe to the Standard annual ...

Nigerians have vowed to drag the federal government to court over approval of a 50 percent increase in calls, data, and other telecommunication tariffs. In an instant multiplier effect ...

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion for the expanded use of the ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended extending marketing authorisation for a subcutaneous (SC) formulation of Rybrevant for treating non-small cell lung cancer ...

“This positive CHMP opinion is a welcome milestone in the treatment of EGFR-mutated NSCLC, with the ability to make a meaningful difference in clinical practice and provide patients with more ...

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered ... customer base (already 50+ million) and a diverse ...

BEERSE, BELGIUM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave its thumbs-up to eight new medicines including two vaccines, two oncology drugs, three biosimilars and ...

(RTTNews) - AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy for limited-stage small cell lung cancer.